

# MEDICAL ONCOLOGY

## Maintenance of Certification Examination (MOC) / General LKA



Effective beginning with the Fall 2026 traditional, 10-year MOC exam and the 2026 Quarter 3 Longitudinal Knowledge Assessment.

**High Relevance:** Topics are very likely to appear on the assessment.

**Medium Relevance:** Topics are moderately likely to appear on the assessment.

**Low Relevance:** Topics will not appear on the assessment.

Blueprint Code and Topic	Assessment Percentage	Diagnosis/ Testing 25%	Treatment/ Care Decisions 60%	RiskAssessment /Prognosis /Epidemiology 10%	Pathophysiology /Basic Science 5%
<b>1 Clinical Research Methodology and Ethics</b>	<b>6.5%</b>				
<b>1.1 Clinical research methodology</b>	<b>4.5%</b>	<b>HIGH</b>	<b>HIGH</b>	<b>HIGH</b>	<b>HIGH</b>
1.1.1 Design and interpretation of clinical trials					
1.1.1.1 Clinical trial design					
1.1.1.2 Clinical trial interpretation					
1.1.2 Tumor assessment, imaging, and end points					
<b>1.2 Ethics</b>	<b>2%</b>	<b>HIGH</b>	<b>HIGH</b>	<b>HIGH</b>	<b>LOW</b>
1.2.1 Human subjects and regulatory and legal issues					
1.2.2 Conflict of interest					
<b>2 Palliative Care, Survivorship, and Oncologic Complications</b>	<b>11%</b>				
<b>2.1 Clinical manifestations of advanced cancer and its treatment</b>	<b>2.5%</b>	<b>HIGH</b>	<b>HIGH</b>	<b>HIGH</b>	<b>HIGH</b>
2.1.1 Cutaneous and mucosal manifestations					
2.1.2 Endocrine manifestations					
2.1.3 Gastrointestinal manifestations					
2.1.4 Hematologic manifestations					
2.1.5 Musculoskeletal manifestations					
2.1.6 Neurologic manifestations					
2.1.7 Renal, metabolic, and nutritional manifestations					
2.1.8 Paraneoplastic syndromes					
2.1.9 Cardiothoracic manifestations					
2.1.10 Fatigue					
2.1.11 Psychiatric manifestations					
2.1.12 Infectious risks and complications					
2.1.13 Lymphedema					
<b>2.2 Cancer pain</b>	<b>3.5%</b>	<b>LOW</b>	<b>HIGH</b>	<b>HIGH</b>	<b>HIGH</b>
2.2.1 Use of opioids					
2.2.2 Use of nonopioids					
<b>2.3 Survivorship issues</b>	<b>1%</b>	<b>HIGH</b>	<b>HIGH</b>	<b>HIGH</b>	<b>HIGH</b>
2.3.1 Fertility and sexual health					
2.3.2 Second primary cancers					
2.3.3 Secondary cancer prevention					

Blueprint Code and Topic	Assessment Percentage	Diagnosis/ Testing 25%	Treatment/ Care Decisions 60%	RiskAssessment /Prognosis /Epidemiology 10%	Pathophysiology /Basic Science 5%
2.3.4 Nonmalignant sequelae					
2.3.5 Surveillance					
<b>2.4 End-of-life issues</b>	2%	HIGH	HIGH	HIGH	HIGH
2.4.1 Hospice					
2.4.2 Feeding and nutrition					
2.4.3 Decision making/communication					
<b>2.5 Communication, including prognosis, goals of care, and survivorship</b>	2%	LOW	HIGH	HIGH	LOW
2.5.1 Communicating prognosis and other clinical information					
2.5.2 Discussing goals of care					
2.5.3 Discussing survivorship issues					
<b>3 Hematologic Neoplasms</b>	<b>13%</b>				
<b>3.1 Acute leukemia and myelodysplasia</b>	2%	HIGH	HIGH	HIGH	MEDIUM
3.1.1 Acute myeloid leukemia (AML)					
3.1.1.1 Acute promyelocytic leukemia (APL)					
3.1.1.2 AML with recurrent genetic abnormalities					
3.1.1.3 AML with myelodysplasia-related changes					
3.1.1.4 AML not otherwise specified					
3.1.1.5 Myeloid sarcoma					
3.1.2 Acute lymphoblastic leukemia/lymphoma					
3.1.3 Myelodysplastic syndromes					
3.1.4 Chronic myelomonocytic leukemia					
<b>3.2 Chronic myeloid leukemia and myeloproliferative neoplasms</b>	2%	HIGH	HIGH	MEDIUM	MEDIUM
3.2.1 Chronic myeloid leukemia					
3.2.2 Myeloproliferative neoplasms					
<b>3.3 Chronic lymphoproliferative leukemias</b>	1%	HIGH	HIGH	MEDIUM	MEDIUM
3.3.1 Chronic lymphocytic leukemia/small lymphocytic lymphoma					
3.3.2 Hairy cell leukemia					
3.3.3 T-cell prolymphocytic leukemia					
3.3.4 T-cell large granular lymphocytic leukemia					
3.3.5 Monoclonal B-cell lymphocytosis					
<b>3.4 Hodgkin lymphoma</b>	1%	HIGH	HIGH	MEDIUM	MEDIUM
3.4.1 Early-stage disease					
3.4.2 Advanced disease					
<b>3.5 Multiple myeloma and plasma cell dyscrasias</b>	3%	HIGH	HIGH	MEDIUM	MEDIUM
3.5.1 Multiple myeloma/plasma cell leukemia					
3.5.2 Solitary plasmacytoma					
3.5.3 Primary amyloidosis					

Blueprint Code and Topic	Assessment Percentage	Diagnosis/ Testing 25%	Treatment/ Care Decisions 60%	RiskAssessment /Prognosis /Epidemiology 10%	Pathophysiology /Basic Science 5%
3.5.4 Monoclonal gammopathy of undetermined significance (MGUS)					
3.5.5 Lymphoplasmacytic lymphoma (including Waldenstrom macroglobulinemia)					
<b>3.6 Non-Hodgkin lymphoma</b>	1%	HIGH	HIGH	MEDIUM	MEDIUM
3.6.1 Diffuse large B-cell lymphoma					
3.6.2 Follicular lymphoma					
3.6.3 Burkitt lymphoma					
3.6.4 Mantle cell lymphoma					
3.6.5 NK-T cell lymphoma					
3.6.6 Anaplastic large cell lymphoma					
3.6.7 Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)					
3.6.8 Nodal marginal zone lymphoma					
3.6.9 Human immunodeficiency virus (HIV)-associated lymphoma					
3.6.10 Cutaneous T-cell lymphoma					
3.6.11 Primary central nervous system lymphoma					
3.6.12 Post-transplantation lymphoproliferative syndromes					
3.6.13 Peripheral T-cell lymphoma					
<b>3.7 Genetics and genomics of hematologic neoplasms</b>	1%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
<b>3.8 Complications of hematologic neoplasm treatment</b>	2%	HIGH	HIGH	MEDIUM	MEDIUM
<b>4 Thoracic Cancer</b>	<b>11.5%</b>				
<b>4.1 Non-small cell lung cancer</b>	4%	HIGH	HIGH	HIGH	MEDIUM
4.1.1 Early-stage disease					
4.1.1.1 Resectable disease					
4.1.1.2 Unresectable disease					
4.1.2 Locally advanced disease					
4.1.2.1 Stage IIIA disease					
4.1.2.2 Stage IIIB disease					
4.1.2.3 Stage IIIC disease					
4.1.3 Metastatic disease					
4.1.3.1 Adenocarcinoma					
4.1.3.2 Squamous cell carcinoma					
<b>4.2 Small cell lung cancer</b>	2%	HIGH	HIGH	MEDIUM	MEDIUM
4.2.1 Limited disease					
4.2.2 Extensive disease					
<b>4.3 Mesothelioma and thymus cancer</b>	1%	MEDIUM	HIGH	MEDIUM	MEDIUM
4.3.1 Mesothelioma					
4.3.2 Thymus cancer					
<b>4.4 Genetics and genomics of thoracic cancer</b>	2%	HIGH	HIGH	MEDIUM	MEDIUM

Blueprint Code and Topic	Assessment Percentage	Diagnosis/ Testing 25%	Treatment/ Care Decisions 60%	RiskAssessment /Prognosis /Epidemiology 10%	Pathophysiology /Basic Science 5%
4.5 Complications of thoracic cancer treatment	2.5%	HIGH	HIGH	MEDIUM	MEDIUM
5 Breast Cancer	13.5%				
5.1 Premalignant conditions and high-risk factors	1%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
5.1.1 High-risk histologies (including atypical ductal hyperplasia and atypical lobular hyperplasia)					
5.1.2 Genetic predispositions					
5.2 Carcinoma in situ	1.5%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
5.3 Early stage and locally advanced invasive carcinoma	3%	HIGH	HIGH	HIGH	MEDIUM
5.3.1 HER2-positive disease					
5.3.2 HER2-negative, hormone receptor-positive disease					
5.3.3 HER2-negative, hormone receptor-negative (triple-negative) disease					
5.4 Inflammatory disease	0.5%	HIGH	HIGH	MEDIUM	MEDIUM
5.5 Locally recurrent disease	0.5%	HIGH	HIGH	MEDIUM	MEDIUM
5.5.1 In-breast recurrence					
5.5.2 Chest wall recurrence					
5.6 Metastatic disease	3%	HIGH	HIGH	MEDIUM	MEDIUM
5.6.1 HER2-positive metastatic disease					
5.6.2 HER2-negative, hormone receptor-positive metastatic disease					
5.6.3 HER2-negative, hormone receptor-negative (triple-negative) metastatic disease					
5.7 Less common clinical scenarios, including tubular carcinoma, male breast cancer, and pregnancy-associated breast cancer	1%	HIGH	HIGH	MEDIUM	MEDIUM
5.7.1 Tubular carcinoma					
5.7.2 Male breast cancer					
5.7.3 Pregnancy-associated breast cancer					
5.8 Genetics and genomics of breast cancer	1.5%	HIGH	HIGH	MEDIUM	MEDIUM
5.9 Complications of breast cancer treatment	1.5%	HIGH	HIGH	HIGH	MEDIUM
6 Genitourinary Cancer	12%				
6.1 Germ cell tumors	1.5%	HIGH	HIGH	MEDIUM	MEDIUM
6.1.1 Seminoma					
6.1.2 Nonseminoma					
6.1.3 Germ cell tumor type not specified					
6.2 Prostate cancer	3%	HIGH	HIGH	MEDIUM	MEDIUM
6.2.1 Localized disease					
6.2.2 Locally advanced disease					
6.2.3 Prostate-specific antigen-only nonmetastatic disease					
6.2.3.1 Castration-sensitive disease					
6.2.3.2 Castration-resistant disease					
6.2.4 Metastatic disease					
6.2.4.1 Metastatic castration-sensitive disease					

Blueprint Code and Topic	Assessment Percentage	Diagnosis/ Testing 25%	Treatment/ Care Decisions 60%	RiskAssessment /Prognosis /Epidemiology 10%	Pathophysiology /Basic Science 5%
6.2.4.2 Metastatic castration-resistant disease					
6.2.5 Special issues in prostate cancer					
6.2.5.1 Small cell carcinoma					
<b>6.3 Renal cell cancer</b>	2.5%	MEDIUM	HIGH	MEDIUM	MEDIUM
6.3.1 Localized disease					
6.3.2 Metastatic disease					
6.3.3 Non-clear cell histologies					
<b>6.4 Urothelial and other genitourinary cancers</b>	2%	MEDIUM	HIGH	MEDIUM	MEDIUM
6.4.1 Bladder cancer					
6.4.1.1 Non-muscle invasive disease					
6.4.1.2 Muscle-invasive disease					
6.4.1.3 Metastatic disease					
6.4.2 Upper tract urothelial cancer and urethral cancer					
6.4.3 Rare histologies					
<b>6.5 Adrenal tumors</b>	0%	LOW	LOW	LOW	LOW
6.5.1 Adrenocortical carcinoma					
6.5.2 Pheochromocytoma and paraganglioma					
6.6 Genetics and genomics of genitourinary cancer	1%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
6.7 Complications of genitourinary cancer treatment	2%	HIGH	HIGH	MEDIUM	MEDIUM
<b>7 Gynecologic Cancer</b>	5.5%				
<b>7.1 Cervical cancer</b>	1%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
7.1.1 Local-regional disease (stages II and III)					
7.1.2 Recurrent and metastatic disease					
<b>7.2 Ovarian, fallopian tube, and primary peritoneal cancers</b>	2%	HIGH	HIGH	MEDIUM	MEDIUM
7.2.1 Epithelial ovarian, fallopian tube, and primary peritoneal cancers					
7.2.1.1 Stage I					
7.2.1.2 Stages II-IV					
7.2.2 Nonepithelial ovarian cancers					
7.2.3 Low malignant potential (borderline) cancers					
<b>7.3 Uterine sarcoma</b>	0.5%	LOW	MEDIUM	LOW	LOW
<b>7.4 Endometrial cancer</b>	0.5%	HIGH	HIGH	MEDIUM	MEDIUM
<b>7.5 Genetics and genomics of gynecologic cancer</b>	0.5%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
<b>7.6 Complications of gynecologic cancer treatment</b>	1%	HIGH	HIGH	MEDIUM	MEDIUM
<b>8 Gastrointestinal Cancer</b>	13.5%				
<b>8.1 Anal cancer</b>	1%	MEDIUM	HIGH	MEDIUM	MEDIUM
8.1.1 Local-regional disease					
8.1.2 Recurrent and metastatic disease					

Blueprint Code and Topic	Assessment Percentage	Diagnosis/ Testing 25%	Treatment/ Care Decisions 60%	RiskAssessment /Prognosis /Epidemiology 10%	Pathophysiology /Basic Science 5%
<b>8.2 Biliary tree and gallbladder cancer</b>	1%	HIGH	HIGH	MEDIUM	MEDIUM
8.2.1 Local-regional disease					
8.2.2 Recurrent and metastatic disease					
<b>8.3 Colorectal cancer</b>	2%	HIGH	HIGH	MEDIUM	MEDIUM
8.3.1 Colon cancer					
8.3.1.1 Local-regional disease					
8.3.1.2 Recurrent and metastatic disease					
8.3.2 Rectal cancer					
8.3.2.1 Local-regional disease					
8.3.2.2 Recurrent and metastatic disease					
<b>8.4 Esophageal cancer</b>	1%	HIGH	HIGH	MEDIUM	MEDIUM
8.4.1 Local-regional disease					
8.4.2 Recurrent and metastatic disease					
<b>8.5 Gastric cancer</b>	1%	HIGH	HIGH	MEDIUM	MEDIUM
8.5.1 Resectable disease					
8.5.2 Unresectable and metastatic disease					
<b>8.6 Hepatocellular cancer</b>	1%	MEDIUM	HIGH	MEDIUM	MEDIUM
8.6.1 Resectable disease					
8.6.2 Unresectable, liver-only disease					
8.6.3 Metastatic disease					
<b>8.7 Gastrointestinal neuroendocrine tumors</b>	1%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
<b>8.8 Pancreatic cancer</b>	1.5%	HIGH	HIGH	MEDIUM	MEDIUM
8.8.1 Resectable disease					
8.8.2 Unresectable disease					
8.8.3 Metastatic and recurrent disease					
<b>8.9 Small bowel and appendiceal cancer</b>	0.5%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
8.9.1 Small bowel cancer					
8.9.2 Appendiceal cancer					
<b>8.10 Genetics and genomics of gastrointestinal cancer</b>	2%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
<b>8.11 Complications of gastrointestinal cancer treatment</b>	1.5%	HIGH	HIGH	MEDIUM	MEDIUM
<b>9 Skin Cancer, Sarcomas, and Unknown Primary Site</b>	<b>7%</b>				
<b>9.1 Melanoma</b>	2.5%	HIGH	HIGH	MEDIUM	MEDIUM
9.1.1 Localized melanoma					
9.1.2 Regional nodal and in-transit metastasis					
9.1.3 Metastatic disease					
<b>9.2 Squamous cell and basal cell cancer of the skin</b>	1%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
9.2.1 Local-regional disease					

Blueprint Code and Topic	Assessment Percentage	Diagnosis/ Testing 25%	Treatment/ Care Decisions 60%	RiskAssessment /Prognosis /Epidemiology 10%	Pathophysiology /Basic Science 5%
9.2.2 Recurrent and metastatic disease					
<b>9.3 Merkel cell carcinoma</b>	0%	LOW	LOW	LOW	LOW
<b>9.4 Bone and soft-tissue sarcomas</b>	1%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
9.4.1 Localized primary disease					
9.4.2 Local disease recurrence					
9.4.3 Metastatic disease					
9.4.4 Gastrointestinal stromal tumor (GIST)					
9.4.4.1 Local-regional disease					
9.4.4.2 Recurrent and metastatic disease					
<b>9.5 Unknown primary site</b>	1%	HIGH	HIGH	MEDIUM	MEDIUM
<b>9.6 Genetics and genomics of skin cancers, sarcomas, and unknown primary site</b>	0.5%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
<b>9.7 Complications of treatment for skin cancers, sarcomas, and unknown primary site</b>	1%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
<b>10 Head, Neck, Thyroid, and Central Nervous System Malignancies</b>	<b>6.5%</b>				
<b>10.1 Squamous cell carcinoma of the head and neck</b>	2%	HIGH	HIGH	MEDIUM	MEDIUM
10.1.1 Human papillomavirus-positive disease					
10.1.1.1 Local-regional disease					
10.1.1.2 Recurrent and metastatic disease					
10.1.2 Human papillomavirus-negative disease					
10.1.2.1 Local-regional disease					
10.1.2.2 Recurrent and metastatic disease					
<b>10.2 Salivary gland tumors</b>	0.5%	MEDIUM	MEDIUM	LOW	LOW
<b>10.3 Thyroid cancer</b>	0.5%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
10.3.1 Papillary					
10.3.2 Medullary					
10.3.3 Anaplastic					
<b>10.4 Nasopharyngeal carcinoma</b>	0.5%	MEDIUM	MEDIUM	LOW	LOW
10.4.1 Local and regional disease					
10.4.2 Metastatic disease					
<b>10.5 Central nervous system malignancies</b>	1.5%	HIGH	HIGH	MEDIUM	MEDIUM
10.5.1 Primary central nervous system lesions					
10.5.1.1 High-grade gliomas (astrocytoma and glioblastoma)					
10.5.1.2 Oligodendroglioma and other central nervous system lesions					
10.5.2 Metastatic central nervous system lesions					
10.5.2.1 Parenchymal metastases					
10.5.2.2 Meningeal metastases					
<b>10.6 Genetics and genomics of head, neck, thyroid, and central nervous system malignancies</b>	0.5%	MEDIUM	MEDIUM	MEDIUM	MEDIUM
<b>10.7 Complications of treatment for head, neck, thyroid, and central nervous system malignancies</b>	1%	HIGH	HIGH	MEDIUM	MEDIUM